Clinical trial
GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Homologous Recombinant Deficient (HRD +) Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)
NCT05659381 is registered in ClinicalTrials.gov with GOG Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Homologous Recombinant Deficient (HRD +) Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)
- Lead sponsor
- GOG Foundation
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- March 8, 2024
- Completion date
- August 1, 2034
- Enrollment
- 220 (estimated)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.
stage iii fallopian tube cancer, stage iii ovarian cancer, stage iii primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer